- Conditions: Adult Lymphocyte Depletion Hodgkin Lymphoma; Adult Lymphocyte Predominant Hodgkin Lymphoma; Adult Mixed Cellularity Hodgkin Lymphoma; Adult Nodular Lymphocyte Predominant Hodgkin Lymphoma; Adult Nodular Sclerosis Hodgkin Lymphoma; Recurrent Adult Hodgkin Lymphoma
Interventions: Drug: gemcitabine hydrochloride; Drug: bendamustine hydrochloride
Sponsors: Ohio State University Comprehensive Cancer Center; Ohio State University Comprehensive Cancer Center
Recruiting - verified February 2012 - Condition: Leukaemia, Lymphocytic, Chronic
Interventions: Biological: Ofatumumab; Drug: Bendamustine
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified May 2012 - Conditions: Leukemia; Lymphoma
Interventions: Drug: Rituximab; Drug: 111In Ibritumumab; Procedure: Planar Scintigraphy Imaging; Drug: 90Y IbritumumabTiuxetan; Drug: Fludarabine; Drug: Bendamustine; Drug: Thymoglobulin; Drug: Tacrolimus; Drug: Methotrexate; Drug: Mycophenolate; Drug: G-CSF; Procedure: Stem Cell Transplantation
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; Spectrum Pharmaceuticals, Inc
Not yet recruiting - verified May 2012 - Condition: Multiple Myeloma
Interventions: Drug: Bendamustine; Drug: Bortezomib; Drug: Lenalidomide; Drug: Dexamethasone
Sponsors: Loyola University; Loyola University
Recruiting - verified December 2011 - Condition: Follicular Lymphoma
Interventions: Drug: Rituximab; Drug: Lenalidomide; Drug: Rituximab-CHOP; Drug: Rituximab-CVP; Drug: Rituximab-Bendamustine
Sponsors: Celgene Corporation; Celgene Corporation; Groupe d'Etude des Lymphomes de l'Adulte - Recherche Clinique
Recruiting - verified April 2012 - Condition: Non-Hodgkin's Lymphoma
Intervention: Drug: Bendamustine + Rituximab + Pixantrone
Sponsors: Duke University; Duke University; Cell Therapeutics
Recruiting - verified March 2012 - Conditions: Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue; Nodal Marginal Zone B-cell Lymphoma; Recurrent Adult Diffuse Large Cell Lymphoma; Recurrent Grade 1 Follicular Lymphoma; Recurrent Grade 2 Follicular Lymphoma; Recurrent Grade 3 Follicular Lymphoma; Recurrent Mantle Cell Lymphoma; Recurrent Marginal Zone Lymphoma; Splenic Marginal Zone Lymphoma; Waldenstrom Macroglobulinemia
Interventions: Drug: BTK inhibitor PCI-32765; Biological: rituximab; Drug: bendamustine hydrochloride; Other: pharmacogenomic studies; Other: pharmacological study; Other: laboratory biomarker analysis
Sponsors: Ohio State University Comprehensive Cancer Center; Ohio State University Comprehensive Cancer Center; Pharmacyclics
Recruiting - verified January 2012 - Condition: Chronic Lymphocytic Leukemia
Intervention: Drug: Maintenance lenalidomide
Sponsors: Yale University; Yale University; Celgene Corporation
Recruiting - verified March 2012 - Condition: Chronic Lymphocytic Leukemia (CLL)
Interventions: Drug: MEDI-551; Drug: Rituximab; Drug: Bendamustine
Sponsors: MedImmune LLC; MedImmune LLC
Recruiting - verified April 2012 - Condition: Non-Hodgkin's Lymphoma
Interventions: Drug: Bendamustine; Drug: Ofatumumab; Drug: Carboplatin; Drug: Etoposide; Procedure: CT Scan; Procedure: PET Scan; Genetic: Stem Cell Transplant (STC)
Sponsors: Thomas Jefferson University; Thomas Jefferson University; GlaxoSmithKline
Recruiting - verified January 2012 - Condition: Mantle Cell Lymphoma
Interventions: Biological: Ofatumumab; Other: Ofatumumab + Bendamustine
Sponsors: Memorial Sloan-Kettering Cancer Center; Memorial Sloan-Kettering Cancer Center; GlaxoSmithKline
Recruiting - verified January 2012 - Condition: Multiple Myeloma
Interventions: Drug: Cyclophosphamide; Drug: Velcade; Drug: Chloroquine
Sponsors: New York University School of Medicine; New York University School of Medicine; Millennium Pharmaceuticals, Inc.
Recruiting - verified April 2012 - Condition: Lymphoma
Interventions: Biological: rituximab; Drug: bendamustine hydrochloride; Drug: cyclophosphamide; Drug: cytarabine; Drug: dexamethasone; Drug: doxorubicin hydrochloride; Drug: leucovorin calcium; Drug: methotrexate; Drug: vincristine sulfate
Sponsors: National Cancer Institute (NCI); Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012 - Conditions: Indolent Non-Hodgkin Lymphoma; Mantle Cell Lymphoma; Chronic Lymphocytic Leukemia
Intervention: Drug: SAR245409
Sponsors: Sanofi-Aventis; Sanofi-Aventis
Recruiting - verified April 2012 - Conditions: Chronic Lymphocytic Leukemia; B-Cell Non-Hodgkin's Lymphoma
Interventions: Drug: Bendamustine; Drug: Pentostatin; Drug: Ofatumumab
Sponsors: Thomas Jefferson University; Thomas Jefferson University; GlaxoSmithKline
Recruiting - verified January 2012 - Conditions: Chronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma; B Chronic Lymphocytic Leukemia
Interventions: Drug: Lenalidomide; Drug: Bendamustine; Drug: Rituximab
Sponsors: Massachusetts General Hospital; Massachusetts General Hospital; Dana-Farber Cancer Institute
Recruiting - verified February 2012 - Condition: Myeloma
Intervention: Drug: Simvastatin,Zoledronic Acid,Bortezomib,Bendamustine,Methylprednisolone.
Sponsors: James Graham Brown Cancer Center; Geoffry Herzig, MD
Recruiting - verified April 2012 - Conditions: Lymphoma; Multiple Myeloma and Plasma Cell Neoplasm; Precancerous Condition; Small Intestine Cancer; Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Biological: rituximab; Drug: bendamustine hydrochloride; Drug: veliparib; Other: laboratory biomarker analysis; Other: pharmacological study
Sponsors: National Cancer Institute (NCI); Memorial Sloan-Kettering Cancer Center; National Cancer Institute (NCI)
Recruiting - verified March 2012 - Condition: Multiple Myeloma
Interventions: Drug: Bendamustine; Drug: Bortezomib
Sponsors: New York University School of Medicine; New York University School of Medicine; Cephalon
Recruiting - verified March 2012 - Condition: Chronic Lymphocytic Leukemia
Interventions: Drug: bendamustine; Drug: cyclophosphamide; Drug: Fludarabine; Drug: RO5072759
Sponsors: Genentech; Genentech
Recruiting - verified March 2012 - Condition: Lymphoma, Non-Hodgkin
Interventions: Biological: Ofatumumab; Drug: Bendamustine
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified December 2011 - Condition: Lymphoma
Interventions: Biological: ofatumumab; Drug: bendamustine hydrochloride; Drug: bortezomib
Sponsors: National Cancer Institute (NCI); Cancer and Leukemia Group B; National Cancer Institute (NCI)
Recruiting - verified May 2012 - Condition: Follicular Lymphoma
Intervention: Drug: HCD122
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified March 2012 - Conditions: Diffuse Large B-Cell Lymphoma; Lymphoma, Diffuse Large-Cell; Diffuse Large-Cell Lymphoma; Lymphoma
Interventions: Drug: Bendamustine; Drug: Rituximab
Sponsors: UNC Lineberger Comprehensive Cancer Center; UNC Lineberger Comprehensive Cancer Center; Cephalon
Recruiting - verified April 2012 - Conditions: Lymphoma, Non-Hodgkin; Lymphoma, B-cell; Lymphoma, B-cell, Diffuse
Interventions: Drug: Inotuzumab ozogamicin; Drug: Rituximab; Drug: rituximab + gemcitabine; Drug: rituximab +bendamustine
Sponsors: Pfizer; Pfizer; UCB, Inc.
Recruiting - verified April 2012 - Condition: Relapsed AL Amyloidosis
Interventions: Drug: Bendamustine; Drug: Dexamethasone
Sponsors: University of Pittsburgh; University of Pittsburgh; Cephalon
Not yet recruiting - verified June 2011 - Condition: Lymphoma, Follicular
Interventions: Drug: Bendamustine; Drug: Rituximab; Radiation: Y-90 ibritumomab
Sponsors: Dartmouth-Hitchcock Medical Center; Dartmouth-Hitchcock Medical Center; Cephalon; Spectrum Pharmaceuticals, Inc
Recruiting - verified October 2011 - Condition: Lymphoma
Interventions: Biological: rituximab; Drug: bendamustine hydrochloride; Drug: bortezomib; Drug: lenalidomide
Sponsors: National Cancer Institute (NCI); Eastern Cooperative Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012 - Condition: Chronic Lymphocytic Leukemia (CLL)
Interventions: Other: TRU-016 and bendamustine; Other: TRU-016 and bendamustine; Drug: Bendamustine
Sponsors: Emergent Product Development Seattle LLC; Emergent Product Development Seattle LLC
Recruiting - verified February 2012 - Bendamustine in Combination With Bortezomib and Pegylated Liposomal Doxorubicin for Multiple MyelomaCondition: Multiple Myeloma
Interventions: Drug: Bendamustine; Drug: Doxorubicin; Drug: Bortezomib; Drug: Bendamustine; Drug: Filgrastim
Sponsors: Hoosier Oncology Group; Hoosier Oncology Group; Cephalon
Recruiting - verified March 2012 - Condition: Advanced Cancer
Interventions: Drug: Bendamustine; Drug: Bevacizumab
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; Cephalon; National Comprehensive Cancer Network
Recruiting - verified March 2012 - Conditions: Adult Grade III Lymphomatoid Granulomatosis; Adult Nasal Type Extranodal NK/T-cell Lymphoma; Anaplastic Large Cell Lymphoma; Angioimmunoblastic T-cell Lymphoma; Chronic Lymphocytic Leukemia; Contiguous Stage II Adult Diffuse Mixed Cell Lymphoma; Contiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma; Contiguous Stage II Adult Immunoblastic Large Cell Lymphoma; Contiguous Stage II Adult Lymphoblastic Lymphoma; Contiguous Stage II Grade 1 Follicular Lymphoma; Contiguous Stage II Grade 2 Follicular Lymphoma; Contiguous Stage II Grade 3 Follicular Lymphoma; Contiguous Stage II Mantle Cell Lymphoma; Contiguous Stage II Marginal Zone Lymphoma; Contiguous Stage II Small Lymphocytic Lymphoma; Cutaneous B-cell Non-Hodgkin Lymphoma; Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue; Intraocular Lymphoma; Nodal Marginal Zone B-cell Lymphoma; Noncontiguous Stage II Adult Diffuse Mixed Cell Lymphoma; Noncontiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma; Noncontiguous Stage II Adult Immunoblastic Large Cell Lymphoma; Noncontiguous Stage II Adult Lymphoblastic Lymphoma; Noncontiguous Stage II Grade 1 Follicular Lymphoma; Noncontiguous Stage II Grade 2 Follicular Lymphoma; Noncontiguous Stage II Grade 3 Follicular Lymphoma; Noncontiguous Stage II Mantle Cell Lymphoma; Noncontiguous Stage II Marginal Zone Lymphoma; Noncontiguous Stage II Small Lymphocytic Lymphoma; Recurrent Adult Burkitt Lymphoma; Recurrent Adult Diffuse Large Cell Lymphoma; Recurrent Adult Diffuse Mixed Cell Lymphoma; Recurrent Adult Diffuse Small Cleaved Cell Lymphoma; Recurrent Adult Grade III Lymphomatoid Granulomatosis; Recurrent Adult Hodgkin Lymphoma; Recurrent Adult Immunoblastic Large Cell Lymphoma; Recurrent Adult Lymphoblastic Lymphoma; Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma; Recurrent Grade 1 Follicular Lymphoma; Recurrent Grade 2 Follicular Lymphoma; Recurrent Grade 3 Follicular Lymphoma; Recurrent Mantle Cell Lymphoma; Recurrent Marginal Zone Lymphoma; Recurrent Mycosis Fungoides/Sezary Syndrome; Recurrent Small Lymphocytic Lymphoma; Small Intestine Lymphoma; Splenic Marginal Zone Lymphoma; Stage I Adult Burkitt Lymphoma; Stage I Adult Diffuse Mixed Cell Lymphoma; Stage I Adult Diffuse Small Cleaved Cell Lymphoma; Stage I Adult Immunoblastic Large Cell Lymphoma; Stage I Adult Lymphoblastic Lymphoma; Stage I Cutaneous T-cell Non-Hodgkin Lymphoma; Stage I Grade 1 Follicular Lymphoma; Stage I Grade 2 Follicular Lymphoma; Stage I Grade 3 Follicular Lymphoma; Stage I Mantle Cell Lymphoma; Stage I Marginal Zone Lymphoma; Stage I Mycosis Fungoides/Sezary Syndrome; Stage I Small Lymphocytic Lymphoma; Stage II Adult Burkitt Lymphoma; Stage II Cutaneous T-cell Non-Hodgkin Lymphoma; Stage II Grade 1 Follicular Lymphoma; Stage II Grade 2 Follicular Lymphoma; Stage II Grade 3 Follicular Lymphoma; Stage II Mycosis Fungoides/Sezary Syndrome; Stage III Adult Burkitt Lymphoma; Stage III Adult Diffuse Mixed Cell Lymphoma; Stage III Adult Diffuse Small Cleaved Cell Lymphoma; Stage III Adult Immunoblastic Large Cell Lymphoma; Stage III Adult Lymphoblastic Lymphoma; Stage III Cutaneous T-cell Non-Hodgkin Lymphoma; Stage III Grade 1 Follicular Lymphoma; Stage III Grade 2 Follicular Lymphoma; Stage III Grade 3 Follicular Lymphoma; Stage III Mantle Cell Lymphoma; Stage III Marginal Zone Lymphoma; Stage III Mycosis Fungoides/Sezary Syndrome; Stage III Small Lymphocytic Lymphoma; Stage IV Adult Burkitt Lymphoma; Stage IV Adult Diffuse Mixed Cell Lymphoma; Stage IV Adult Diffuse Small Cleaved Cell Lymphoma; Stage IV Adult Immunoblastic Large Cell Lymphoma; Stage IV Adult Lymphoblastic Lymphoma; Stage IV Cutaneous T-cell Non-Hodgkin Lymphoma; Stage IV Grade 1 Follicular Lymphoma; Stage IV Grade 2 Follicular Lymphoma; Stage IV Grade 3 Follicular Lymphoma; Stage IV Mantle Cell Lymphoma; Stage IV Marginal Zone Lymphoma; Stage IV Mycosis Fungoides/Sezary Syndrome; Stage IV Small Lymphocytic Lymphoma; Waldenström Macroglobulinemia
Interventions: Drug: bendamustine hydrochloride; Drug: carboplatin; Biological: rituximab; Drug: etoposide
Sponsors: Fred Hutchinson Cancer Research Center; Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium; National Cancer Institute (NCI)
Recruiting - verified May 2012 - Conditions: Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities; Adult Acute Myeloid Leukemia With Del(5q); Adult Acute Myeloid Leukemia With Inv(16)(p13;q22); Adult Acute Myeloid Leukemia With t(15;17)(q22;q12); Adult Acute Myeloid Leukemia With t(16;16)(p13;q22); Adult Acute Myeloid Leukemia With t(8;21)(q22;q22); de Novo Myelodysplastic Syndromes; Myelodysplastic Syndrome With Isolated Del(5q); Untreated Adult Acute Myeloid Leukemia
Interventions: Drug: bendamustine hydrochloride; Drug: idarubicin
Sponsors: Fred Hutchinson Cancer Research Center; Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium; National Cancer Institute (NCI)
Recruiting - verified March 2012 - Conditions: Adult Nasal Type Extranodal NK/T-cell Lymphoma; Anaplastic Large Cell Lymphoma; Angioimmunoblastic T-cell Lymphoma; Cutaneous B-cell Non-Hodgkin Lymphoma; Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue; Intraocular Lymphoma; Nodal Marginal Zone B-cell Lymphoma; Peripheral T-cell Lymphoma; Recurrent Adult Burkitt Lymphoma; Recurrent Adult Diffuse Large Cell Lymphoma; Recurrent Adult Diffuse Mixed Cell Lymphoma; Recurrent Adult Diffuse Small Cleaved Cell Lymphoma; Recurrent Adult Grade III Lymphomatoid Granulomatosis; Recurrent Adult Hodgkin Lymphoma; Recurrent Adult Immunoblastic Large Cell Lymphoma; Recurrent Adult Lymphoblastic Lymphoma; Recurrent Adult T-cell Leukemia/Lymphoma; Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma; Recurrent Grade 1 Follicular Lymphoma; Recurrent Grade 2 Follicular Lymphoma; Recurrent Grade 3 Follicular Lymphoma; Recurrent Mantle Cell Lymphoma; Recurrent Marginal Zone Lymphoma; Recurrent Mycosis Fungoides/Sezary Syndrome; Recurrent Small Lymphocytic Lymphoma; Refractory Multiple Myeloma; Small Intestine Lymphoma; Splenic Marginal Zone Lymphoma; Waldenström Macroglobulinemia
Interventions: Drug: bendamustine hydrochloride; Drug: dexamethasone; Biological: filgrastim; Procedure: leukapheresis; Other: laboratory biomarker analysis; Other: flow cytometry; Drug: etoposide
Sponsors: Fred Hutchinson Cancer Research Center; Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium; National Cancer Institute (NCI)
Recruiting - verified May 2012 - Condition: Leukemia
Interventions: Drug: Bendamustine; Drug: Fludarabine; Drug: Rituximab
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Recruiting - verified February 2012 - Conditions: Indolent Non-Hodgkin's Lymphoma; Chronic Lymphocytic Leukemia; Mantle Cell Lymphoma
Interventions: Drug: CAL-101; Drug: Rituximab; Drug: Bendamustine; Drug: Ofatumumab; Drug: Fludarabine; Drug: Everolimus; Drug: Bortezomib; Drug: Chlorambucil
Sponsors: Gilead Sciences; Gilead Sciences
Recruiting - verified April 2012 - Conditions: Lymphoma, Non-Hodgkin; Lymphoma, Follicular
Interventions: Drug: Ofatumumab and Bendamustine infusions (Arm A); Drug: Bendamustine infusion (Arm B)
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified March 2012 - Conditions: Non-Hodgkin's Lymphoma; Mantle Cell Lymphoma
Intervention: Drug: bendamustine and rituximab
Sponsors: Teva Pharmaceutical Industries; Cephalon
Recruiting - verified May 2012 - Condition: Hairy Cell Leukemia
Interventions: Drug: Pentostatin; Drug: Rituximab; Drug: Bendamustine
Sponsors: National Institutes of Health Clinical Center (CC); National Cancer Institute (NCI)
Recruiting - verified August 2011 - Condition: Non-Hodgkin's Lymphoma
Interventions: Drug: bendamustine; Drug: RO5072759
Sponsors: Genentech; Genentech; Roche Pharma AG
Recruiting - verified May 2012 - Condition: Refractory Multiple Myeloma
Interventions: Drug: bendamustine hydrochloride; Drug: lenalidomide; Drug: dexamethasone
Sponsors: Mayo Clinic; Mayo Clinic
Recruiting - verified April 2012 - Condition: Lymphoma
Interventions: Drug: Bendamustine; Drug: Bortezomib; Drug: Rituximab
Sponsors: Sarah Cannon Research Institute; Sarah Cannon Research Institute; Millennium Pharmaceuticals, Inc.; Cephalon
Recruiting - verified July 2011 - Condition: Lymphoma
Interventions: Drug: Rituximab; Drug: Bendamustine
Sponsors: University of Kansas; University of Kansas; Cephalon
Recruiting - verified October 2011 - Conditions: Chronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma
Intervention: Drug: Ofatumumab and Bendamustine
Sponsors: Georgetown University; Georgetown University; GlaxoSmithKline; Cephalon
Recruiting - verified October 2011 - Condition: Lung Cancer
Intervention: Drug: bendamustine hydrochloride
Sponsors: Vanderbilt-Ingram Cancer Center; Vanderbilt-Ingram Cancer Center; National Cancer Institute (NCI)
Recruiting - verified October 2011 - Conditions: Chronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma
Interventions: Drug: Bendamustine; Drug: Rituximab; Drug: Lenalidomide
Sponsors: University of Wisconsin, Madison; University of Wisconsin, Madison; Celgene Corporation
Recruiting - verified December 2011 - Condition: Chronic Lymphocytic Leukemia
Interventions: Drug: Lenalidomide; Drug: Fludarabine; Drug: Rituximab; Drug: Thymoglobulin; Procedure: Stem Cell Transplantation; Drug: Bendamustine; Drug: Allopurinol
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; Celgene Corporation
Recruiting - verified May 2012 - Conditions: Leukemia; Lymphoma
Interventions: Drug: Bendamustine; Drug: Rituximab; Drug: Fludarabine; Procedure: Stem Cell Transplant (SCT)
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; Cephalon
Recruiting - verified April 2012 - Condition: Brain Metastases
Intervention: Drug: Bendamustine
Sponsors: H. Lee Moffitt Cancer Center and Research Institute; H. Lee Moffitt Cancer Center and Research Institute; National Comprehensive Cancer Network; Cephalon
Recruiting - verified February 2012 - Conditions: Chronic Lymphocytic Leukemia; Non-Hodgkin's Lymphoma
Interventions: Drug: bendamustine and lenalidomide; Drug: BL-NHL; Drug: BLR-CLL; Drug: BLR-NHL
Sponsors: Georgetown University; Georgetown University; Celgene Corporation; Cephalon
Recruiting - verified April 2012 - Conditions: Small Cell Lung Cancer; Extensive Stage; Chemonaive
Intervention: Drug: Bendamustine, Irinotecan, Etoposide/Carboplatin
Sponsors: University of Alabama at Birmingham; University of Alabama at Birmingham; National Comprehensive Cancer Network
Recruiting - verified April 2012 - Bendamustine and Radiation Therapy in Treating Patients With Brain Metastases Caused by Solid TumorsConditions: Metastatic Cancer; Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Drug: bendamustine; Other: laboratory biomarker analysis; Procedure: therapeutic conventional surgery; Radiation: stereotactic body radiation therapy
Sponsors: Ohio State University Comprehensive Cancer Center; Ohio State University Comprehensive Cancer Center; National Comprehensive Cancer Network
Recruiting - verified March 2012 - Conditions: Adult Anaplastic Astrocytoma; Adult Anaplastic Oligodendroglioma; Recurrent Adult Brain Tumor
Interventions: Drug: bendamustine hydrochloride; Procedure: quality-of-life assessment
Sponsors: Fred Hutchinson Cancer Research Center; Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium; National Comprehensive Cancer Network; National Cancer Institute (NCI)
Recruiting - verified April 2012
 |
Bendamustine Clinical Trials |
